Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550847 | 1.00 | QPCT (0.45) | QPCTKDRSHMT2RPS6KB1ADORA2A | |
| SCHEMBL29551454 | 0.86 | KDR (0.45) | QPCTKDRBACE1KDM4E | |
| SCHEMBL20522328 | 0.86 | KDR (0.45) | QPCTKDRBACE1KDM4E | |
| SCHEMBL20522358 | 0.84 | QPCT (0.47) | QPCTKDRSHMT2NAMPTKDM4E | |
| SCHEMBL29550383 | 0.84 | QPCT (0.47) | QPCTKDRSHMT2NAMPTKDM4E | |
| SCHEMBL20522432 | 0.84 | QPCT (0.47) | QPCTKDRSHMT2NAMPT | |
| SCHEMBL29550580 | 0.84 | QPCT (0.47) | QPCTKDRSHMT2NAMPT | |
| SCHEMBL20522411 | 0.82 | QPCT (0.45) | QPCTKDRSHMT2ADORA2AADORA2B | |
| SCHEMBL22712387 | 0.82 | QPCT (0.45) | QPCTKDRKDM4EGRM4 | |
| SCHEMBL29550630 | 0.82 | QPCT (0.45) | QPCTKDRKDM4EGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | claimed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | claimed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | claimed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | QPCT 6/4885KDR 2611/4885SHMT2 535/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | QPCT 3/4885KDR 2432/4885SHMT2 571/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | QPCT 2/4885KDR 2483/4885SHMT2 512/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | QPCT 2/4885KDR 2197/4885SHMT2 515/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | QPCT 3/4885KDR 2829/4885SHMT2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.